In This Section
- News by Topic
- Media Resources
- University Events
- 5K Race for Humanity
- Advances in Pharmacy Practice
- Alumni Reunion Weekend
- Continuing Pharmacy Education
- Delivering Medication Therapy Management Services Certificate Program
- Discover Series
- Family Fall Fest
- Founders’ Day
- Graduate Student Orientation
- Healthy Lifestyles Social Media Business Competition
- Lois K. Cohen Lecture Series
- Making the Connections
- The Bernard J. Malis Memorial Lectureship in Humanities
- Misher Festival of Fine Arts and Humanities
- MLK Day of Service
- Patricia Leahy Memorial Lecture
- Pharmacy-Based Immunization Delivery Training
- Philadelphia Grain Malt Symposium
- Philadelphia Science Festival
- REEP Annual Symposium and Networking Event
- Research Day
- Undergraduate Research Symposium
- Welcome Week
- Alpha Chi Induction Dinner
- USciences in the News
- The Bulletin Alumni Magazine
- The Insider Newsletter Signup
For at least the next year, Enzium, a start-up biotechnology company, will be taking residence on the third floor of University of the Sciences’ McNeil Science and Technology Center. Enzium is leasing the space for manufacturing and further development of fluorescent reagent kits for selective detection of protease enzyme activity.
USciences biology chair PETER B. BERGET, PhD, a cofounder of the company when he was at Carnegie Mellon University (CMU),
was instrumental in establishing its presence at USciences. His cofounder is CEO Crystal
Falco, who also worked on developing the underlying technology while at CMU. Enzium
offers a handful of off-the-shelf fluorescence-based detection kits and is developing
a custom reagent service based on its proprietary technology.
The establishment of a start-up company at USciences is a first for the University. In addition to adding a new dimension to the campus from a research and entrepreneurial aspect, the company will provide exposure to students interested in gaining behind-the-scenes insight into the business world.
“Students have natural curiosity and interest in entrepreneurism in biotechnology. I think Enzium’s presence provides them with access to answers to their questions,” Dr. Berget said.
Currently, Enzium is packaging protease detection kits for research and development applications in academic labs, government labs, and commercial labs. Enzium reagents are unique compared to competitors’ because they are based on an engineered protein platform and can incorporate very long protease recognition sequences. This unique platform allows Enzium to quickly build very selective reagents for difficult-to-detect proteases using the proteases’ natural substrates.
“We’re a little bit different,” said Falco. “Our biosensors are much more selective for the enzyme targets. Proteases look for what are called amino acid recognition sequences. Our competitors can build in very short amino acid sequences, but it turns out a lot of proteases like longer sequences, and that is something only we can accommodate.”
The kits retail between $650 and $750, and depending on the research application used,
researchers can get anywhere from 100 to 400 samples tested with one kit.
On a parallel track, Dr. Berget’s research lab at the University is aiming to develop biosensor reagents for new proteases that can then be licensed to the company.
“Enzium hopes to have the opportunity to collaborate with academic and commercial labs, while the company looks for licensable technologies that have high commercial potential,” Falco said. “Sometimes those things [academic and commercial projects] overlap, but oftentimes they don’t, but we can assume at some point we will have some converging interests.”
In the short amount of time that Enzium has been at USciences, Falco has already informally talked to students, answering questions on business models and startup company strategies in general. She indicated that there might be student internship opportunities with Enzium as the business grows.
In addition to the research space provided by the University, Enzium is receiving backing from BioAdvance through its Greenhouse Fund. “Enzium is one of the first BioAdvance companies from outside of Philadelphia to be attracted to the area,” Falco said of the funding.
“I know USciences president Dr. HELEN GILES-GEE is interested in University– corporate partnerships and this might be a sign of more things to come,” Dr. Berget said. “I think it’s a win all around, and I’m glad it has started.”
When asked whether Dr. Berget’s view was correct, President Giles-Gee responded emphatically, “You bet! Past history has shown that University of the Sciences has encouraged innovators and start-up businesses. We want to capitalize on the core research strengths of the University in ways that generate benefits for faculty and students, incubating and developing businesses as well as the economic development of the region. I am very pleased with what Dr. Berget and associates are doing here.”
For more on the exciting research conducted at USciences, click here.
For more on Enzium, visit their website.